Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:UBIO ProShares UltraPro Nasdaq Biotechnology (UBIO) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock Analysis About ProShares UltraPro Nasdaq Biotechnology (NASDAQ:UBIO) 30 days 90 days 365 days Advanced Chart Get UBIO alerts:Sign Up Key Stats Today's Range$17.61▼$17.6150-Day Range$17.61▼$17.7752-Week Range$13.13▼$35.36VolumeN/AAverage Volume42,922 shsMarket Capitalization$14.97 millionAssets Under Management$27.06 millionDividend Yield0.00%Net Expense Ratio0.95%Aggregate RatingN/A ETF OverviewRead More… ProShares UltraPro Nasdaq Biotechnology ExpensesTypeUBIOHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.75%0.57%0.56%0.51%0.53%Other Expenses0.57%0.30%0.50%0.47%0.53%Total Expense1.32%0.70%0.72%0.67%0.71%Fee Waiver-0.37%-0.45%-0.50%-0.32%-0.56%Net Expense0.95%0.61%0.62%0.60%0.60% Receive UBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProShares UltraPro Nasdaq Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address UBIO ETF News HeadlinesMoleculin Biotech Stock (NASDAQ:MBRX) Dividends: History, Yield and DatesDecember 27, 2023 | benzinga.comProShares Trust - ProShares Ultra Nasdaq Cloud Computing (NASDAQ: SKYU)November 6, 2023 | fool.comNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of companies partnering with Nvidia on its latest AI Superproject … Companies we refer to as Nvidia's "Silent Partners" … And they could benefit greatly as well on Feb. 26.February 24, 2025 | Weiss Ratings (Ad)ProShares UltraPro Short Nasdaq BiotechnologyAugust 8, 2023 | thestreet.comPharmaCyte Biotech Stock (NASDAQ:PMCB), Quotes and News SummaryJanuary 5, 2023 | benzinga.comSee More Headlines UBIO ETF - Frequently Asked Questions What other stocks do shareholders of ProShares UltraPro Nasdaq Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares UltraPro Nasdaq Biotechnology investors own include Alibaba Group (BABA), Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria (CRESW), Markel Group (MKL), NVIDIA (NVDA), Shopify (SHOP) and Energous (WATT). Fund Details IssuerProShares Fund NameProShares UltraPro NASDAQ Biotechnology Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:UBIO Inception Date6/22/2015 Fund ManagerMichael Neches, Tarak Dave WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkNASDAQ Biotechnology Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings0 Fund Statistics Assets Under Management$27.06 million Average Daily Volume$58,712.30 Discount/Premium-0.04% Administrator, Advisor and Custodian AdministratorJ.P. Morgan Investor Services Co. AdvisorProShare Advisors LLC CustodianJPMorgan Chase Bank, N.A. DistributorSEI Investments Distribution Co. Transfer AgentJPMorgan Chase Bank, N.A. TrusteeN/A Lead Market MakerVirtu Financial Miscellaneous Outstanding Shares850,000BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report UBIO Sector ExposureUBIO Industry Exposure This page (NASDAQ:UBIO) was last updated on 2/24/2025 by MarketBeat.com Staff From Our PartnersMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredShocking new Trump video releasedThe 10 Stocks Guaranteed To Boom With Trump Back In Office I’m not talking about Tesla or Palantir… Trum...Porter & Company | SponsoredIgnore Fox Business’s “man who calls it all” at your perilThis is the biggest AI investment story you’ve never been told… and people who invest before March 19 could st...The Oxford Club | SponsoredThis Crypto Is Set to Explode in FebruaryA little-known IRS loophole has been gaining serious attention... If you have a retirement account, you can...Premier Gold Co | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProShares UltraPro Nasdaq Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share ProShares UltraPro Nasdaq Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
